The U.S. Food and Drug Administration (FDA) has accepted Ascentage Pharma‘s Investigational New Drug (IND) application for APG-1387, allowing Ascentage to test the…
A Japanese study has found that an active structure of the protein integrin β7 is specific to multiple myeloma cells, suggesting that it could be…
The first patient-led crowdsourcing and crowdfunding initiative for multiple myeloma (MM) research has exceeded its goal of raising $500,000 to advance new…
Janssen Pharmaceuticals has requested the U.S. Food and Drug Administration (FDA) add a new indication for Darzalex (daratumumab) in combination with other therapies…
Adaptive Biotechnologies has partnered with Amgen to use Adaptive’s NGS-based clonoSEQ Assay in a Phase 3 clinical trial led by Amgen to…
Janssen Pharmaceuticals recently submitted a Type 2 variation application to the European Medicines Agency (EMA) seeking to broaden the existing marketing authorization for…
Poseida Therapeutics is developing CAR T-cell therapies that can get rid of cancer-generating bone marrow cells before a blood cancer patient receives a stem…
Janssen plans to share new data from Phase 3 trials of Darzalex (daratumumab) for multiple myeloma at the 59th American Society of Hematology (ASH) Annual…
Initial data from a Phase 1 study of bluebird bio’s second-generation CAR T-cell therapy bb2121 for relapsed or refractory multiple myeloma showed impressive results,…
A recent update on Cellectar Biosciences’ Phase 1 trial revealed that heavily treated myeloma patients who received the lowest dose of CLR 131 survived for a…